



Utah Department of Health

Guidance on the Suggested Use of Medical Cannabis Chronic Pain

About this document: The following information on the use of medical cannabis serves as a suggested use guide for those participating in the Utah Medical Cannabis Program. The intended audience for this document includes qualified medical providers, pharmacy medical providers, patients intending to use medical cannabis, and caregivers of patients intending to use medical cannabis.

This document details the guidance on the use of medical cannabis for chronic pain. This document does not include general instructions on the use of medical cannabis, contraindications, warnings, precautions and adverse reactions to using cannabis and drug-to-drug interactions which could be found in the extended guidance document titled *Guidance on the Suggested Use of Medical Cannabis*. The extended guidance document can be found on the Utah Department of Health Center for Medical Cannabis website (www.medicalcannabis.utah.gov).

About the authors: This document was authored by the Utah Cannabinoid Product Board and Utah Department of Health staff.

About the Utah Cannabinoid Product Board: Under Utah Health Code 26-61-201, the Cannabinoid Product Board is a board of medical research professionals and physicians who meet on a voluntary basis to review and discuss any available scientific research related to the human use of cannabis, cannabinoid product or an expanded cannabinoid product that was conducted under a study approved by an Institutional Review Board (IRB) or was conducted and approved by the federal government.

DISCLAIMER

The following information on the use of medical cannabis serves as a suggested use guide for those participating in the Utah Medical Cannabis Program. This document has been vetted and approved by the Utah Cannabinoid Product Board under Utah Health Code 26-61-202.

This document is a summary of available peer-reviewed literature concerning potential therapeutic uses and harmful effects of cannabis and cannabinoids. With the ongoing nature of cannabis and cannabinoid research, it is not meant to be complete or comprehensive and should be used as a limited complement to other reliable sources of information. This document is not a systematic review or meta-analysis of the literature and has not rigorously evaluated the quality and weight of the available evidence. There is a lack of controlled clinical trials yielding high level evidence of predictable therapeutic benefit for any given condition other than those for FDA approved formulations. This document includes warnings and risks related to the use of cannabis including cannabis use disorder, potentially irreversible brain damage/mental illness, and legal liability for DUI and potential for adverse work-related consequences.

All patrons participating in the Utah Medical Cannabis Program are advised to use this document and any such document produced from this original document as informational and educational. The use of medical cannabis is at one's own risk. **Medical cannabis is NOT a first line therapy for most medical conditions.**

The information in this document is intended to help as far as available data allows Utah health care decision-makers, health care professionals, health systems leaders, and Utah Medical Cannabis patients to make well-informed decisions and thereby improve the quality of health care outcomes in patients using medical cannabis use. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process.

Smoking cannabis is not permitted under the Utah Medical Cannabis Act. Any mention of smoking in this document refers to the method of use for a particular study and is being stated in the document as a for your information only. The Utah Department of Health, the Cannabinoid Product Board and the State of Utah do not promote smoking as a method of cannabis use.

The Utah Department of Health (UDOH) and the Utah Cannabinoid Product Board (CPB) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by the UDOH and the CPB in this document is accurate, the UDOH does not make any guarantees to that effect. The UDOH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of the UDOH. The UDOH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. The UDOH does not have control over the content of such sites. The UDOH does not make any guarantee with respect to any information contained on such third-party sites and the UDOH is not responsible for any injury, loss, or damage suffered as a

result of using such third-party sites. The UDOH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of UDOH and do not necessarily represent the views of the federal government or any third-party supplier of information. This document is prepared and intended for use in the context of the Utah Medical Cannabis Act. The use of this document outside of Utah is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the State of Utah applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the State of Utah.

The copyright and other intellectual property rights in this document are owned by the UDOH and its licensors. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to the UDOH, the CPB and its licensors.

IMPORTANT NOTE: As always, in the event of significant side effects, stop use of medical cannabis until side effects have resolved, and then reduce to previous, best-tolerated dose. To avoid unwanted psychoactive side effects, “**start low and go slow**” especially when using cannabis products for the first time or using new dosages or types of products.

There is moderate evidence to support the conclusion that medical cannabis and cannabinoids can have clinically significant beneficial effects in the management of chronic pain, particularly pain that is due to nerve damage or neuropathy. This is based on supportive findings from good to fair quality controlled clinical trials with very few opposing findings.

Smoking cannabis is not permitted under the Utah Medical Cannabis Act. Any mention of smoking in this document refers to the method of use for a particular study and is being stated in the document as a for your information only. The Utah Department of Health, the Cannabinoid Product Board and the State of Utah do not promote smoking as a method of cannabis use.

Chronic pain is the most common condition (87-94%) cited by individuals who are seeking to use cannabis for medical purposes (National Academies of Sciences, Engineering, and Medicine, 2017a). A meta-analysis (Whiting et al., 2015) of eight placebo-controlled trials involving 254 patients with chronic pain showed >30% reduction in pain in 37% of patients using cannabis or cannabinoids compared to 31% of patients getting placebo (OR, 1.41 [95% CI, 0.99-2.00]; eight trials). Seven of these eight trials used **nabiximols, an oral mucosal spray with a 1:1 ratio of THC:CBD**, and one trial using **smoked inhaled cannabis**. The single placebo-controlled trial in this review that used smoked cannabis (3.6% THC) looked at patients with pain due to HIV-associated peripheral neuropathy and showed an odds ratio for significant pain reduction of 3.43 (CI = 1.03-11.48) when compared with placebo (Abrams et al., 2007).

A 2015 systematic review looked at **chronic peripheral neuropathic pain** treated with inhaled forms of cannabis (smoked or vaporized flower) (Andreae et al., 2015). Underlying conditions included neuropathy due to HIV, trauma, spinal cord injury, diabetes mellitus, and complex regional pain syndrome. In this review meta-analysis of five randomized placebo-controlled trials performed in the USA involving a total of 178 middle-aged patients showed an odds ratio for significant pain relief (>30% reduction) of 3.22 (CI = 1.59 – 7.42) when compared with placebo and that inhaled cannabis appeared to provide significant short term relief from chronic neuropathic pain for one in 5-6 patients being treated.

A review on the use of smoked cannabis for the treatment of **neuropathic pain** suggested that the efficacy of smoked cannabis (NNT = 3.6, for a 30% reduction in pain) was comparable to that of traditional therapeutic agents (e.g. gabapentin, NNT = 3.8), slightly less than that observed with tricyclic antidepressants (NNT = 2.2), but better than lamotrigine (NNT = 5.4) and selective serotonin reuptake inhibitors (NNT = 6.7) (Grant, 2013). In this review the

concentrations of THC in smoked cannabis ranged between 2% and 9% with an average concentration of 4% yielding good efficacy. Furthermore, the authors suggest that cannabis may present a reasonable alternative or adjunctive treatment for patients with severe, refractory painful peripheral neuropathy who have tried other therapeutic avenues without satisfactory results.

A 12-week blinded randomized placebo-controlled study from England (2012) involved 279 patients with **stable multiple sclerosis** (Zajicek et al., 2012). Active treatment (N= 144) was an oral extract from Cannabis sativa in soft gelatin capsules containing cannabidiol (range 0.8 -1.8 mg) and Δ9 THC (2.5mg). Treatment consisted of a starting dose of one capsule (2.5mg Δ9 THC) twice per day with two-week dose titration phase and a ten-week maintenance phase. Total treatment duration was 12 weeks. Participants were assessed at two, four, eight, and 12 weeks after the start of treatment. The maximum allowable total daily dose was 25mg Δ9 THC. By the end of the 12-week study, 46% of those receiving the active oral cannabis extract treatment had self-titrated to maximum dose of 25mg/day of Δ9 THC vs. 70% of the placebo group. The rate of relief from muscle stiffness and body pain after 12 weeks was almost twice as high with oral cannabis extract group than with placebo (29.4% vs 15.7%; OR 2.26; 95% CI 1.24 to 4.13; p=0.004). Adverse reactions were mild to moderate in intensity and were two times more frequent in the treatment group than the placebo group

The 2017 report from the National Academies of Sciences Medicine and Engineering on the health effects of cannabis concludes that *“There is substantial evidence that cannabis is an effective treatment for chronic pain in adults”* (National Academies of Sciences, Engineering, and Medicine, 2017b). However, the authors of this report also **cautiously note** that only a handful of studies have evaluated the use of cannabis in the United States and all of them evaluated cannabis in flower form provided by the National Institute on Drug Abuse. They also note that many of the cannabis products that are sold in state-regulated markets bear little resemblance to the products that are available for research at the federal level in the United States and that very little is known about the efficacy, dose, routes of administration, or side effects of commonly used and commercially available cannabis products in the United States.

In summary, most systematic reviews of controlled clinical trials using cannabis and cannabis-based medicines, support the conclusion that cannabis and cannabis-based medicines demonstrate a modest analgesic effect and provide an option for treatment of chronic non-cancer pain - particularly chronic neuropathic pain that has not adequately responded to treatment attempts using FDA-approved conventional treatments and interventions (Health Canada, 2018).

General considerations for recommending medicinal cannabis in the treatment of chronic pain (adapted from MacCallum and Russo, 2018):

1. In some patients, oral preparations may be more helpful than vaporized cannabis flower due to longer duration of action of oral preparations and first-pass hepatic metabolism of orally ingested THC to 11-hydroxy THC (more potent than THC).
2. In patients using orally ingested cannabis-based medicines for treatment of pain, sublingual administration of medical cannabis extracts, vaporization of cannabis flower, or use of a medical cannabis vape pen, can be utilized as add-on treatments for episodic exacerbations of symptoms.

3. CBD may attenuate THC side-effects, which may be useful for daytime dosing, or when driving is required.
4. Medical cannabis patients, in contrast to recreational users, frequently use chemotypes with significant amounts of CBD and generally use the smallest amount of THC needed to get the greatest improvement in symptom control, function, and quality of life, with the fewest adverse events.
5. Data from blinded controlled clinical trials comparing various ratios of CBD:THC and therapeutic synergy (entourage effect) of various cannabis chemotypes and cultivars are lacking, but anecdotal reports and preclinical and observational data suggest that terpenoids and phytocannabinoids other than THC and CBD may have some pain-reducing and/or anti-inflammatory effects, and relative amounts of CBD may alter the effects and side-effects of THC (Russo, 2011). Because of this, changing ratios of CBD:THC or using a different chemotype or cultivar may result in improved outcomes in pain management with fewer side-effects in the individual patient where N=1.
6. Management of pain using medical cannabis may follow a bell-shaped dose-response curve and escalation of doses of medical cannabis products past a certain amount may not always result in improved control of pain and in some cases may actually result in loss of therapeutic effect along with increased risk of adverse reactions (Portenoy et al., 2012).
7. THC tolerance may be abrogated via a drug vacation of at least 48 hours, preferably longer. Patients may then find that much lower doses provide symptomatic benefit equal to or better than previously experienced (see suggested regimen devised by Dustin Sulak, DO: <https://healer.com/programs/strategies-for-non-psychoactive-cannabis-use/>).
8. Patients should keep a 'symptom inventory' chart indicating response or efficacy for each cannabis product for each symptom as an aid for qualified medical providers in determining treatment response to medical cannabis in follow up visits.
(See Patient Tracking Journal at the end of this document).

Treatment suggestions for use of orally ingested extracts of Cannabis for Cannabis-naïve individuals with chronic pain (adapted from MacCallum and Russo, 2018):

1. Review currently-used prescription medications and check for drug-drug interactions between THC/CBD and any prescribed medications the individual is taking.
2. When treating chronic pain, consider beginning treatment with a chemotype containing both THC and CBD. Anecdotal reports from some experienced cannabis treatment providers suggest that a product with a 1:1 ratio of CBD:THC (chemotype II) or higher levels of CBD is a reasonable starting place with lower risk of adverse reactions.¹ However, based on other anecdotal reports, some individuals may do subjectively better with other CBD:THC ratios (CBD predominant chemotype III, or THC predominant chemotype I) or cultivars containing higher levels of other specific cannabinoids and/or terpenes.
3. Follow general dosing titration recommendations for orally-administered medical cannabis cited earlier in this document
4. Do not expect rapid onset of analgesia using orally-administered cannabis extracts. Orally-ingested THC is metabolized to 11-hydroxy THC during first-pass hepatic metabolism. 11-hydroxy THC is up to 5x more potent than THC and can cause significant intoxication and bothersome adverse reactions, especially in cannabis-naïve

individuals. Absorption of orally-administered medical cannabis products and the 11-hydroxylation process may take several hours and can be variable depending on bioavailability factors such as concurrent dietary intake. **Start low and go slow.**

5. Absorption and bioavailability of orally-administered cannabis-based medicines are usually increased when taken with a fatty meal.
6. If treatment of acute exacerbations of chronic pain is desired, the use of sublingually administered cannabis extract, or inhalation of vaporized flower or vaporized cannabis extract (vape pen) may be preferable to orally ingested (swallowed) cannabis extract due to relatively rapid onset of effects with these alternative treatment modalities. Follow the general dosing suggestions in this document for vaporization of herbal cannabis or use of a vape pen.

PATIENT TRACKING JOURNAL

The following medical cannabis logbook is for the patient or caregiver to utilize and keep track of the effects of medical cannabis use on underlying disease symptoms and the strains/hybrids that were used in between patient visits to the medical cannabis pharmacy or to his/her qualified medical provider.

It is requested that a patient or a caregiver presents this information to the medical cannabis pharmacy or the qualified medical provider to specifically convey information regarding the efficacy of the medical cannabis that was utilized.

This journal is completely optional to use. Patient and/or caregivers have **no requirement** to use this journal. This journal can be useful to help a pharmacist, or the medical provider understand a patient's symptom levels.

Note: Not every symptom and its scale will apply to every patient. Every patient is unique and may have different symptoms in their treatment/therapy process.

Warning: Smoking medical cannabis is not permitted in the State of Utah.

				RATE THE LEVEL OF PAIN OR DISCOMFORT FOR ANY OF THE FOLLOWING THAT OCCURRED--WITH 1 BEING MILD AND 10 BEING SEVERE (for example, "Pain 8" or "Sleep Disturbance 6"		
DATE	PRODUCT DESCRIPTION	DOSAGE	METHOD OF CONSUMPTION	BEFORE USE	AFTER USE	POST-USE REPORT (LIST ANY OTHER SIDE EFFECTS AND ITS SEVERITY YOU WOULD LIKE TO MENTION)
				Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	
				Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	
				Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	

				Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	
				Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	
				Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	
				Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	
				Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	
				Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	Pain _____ Agitation _____ Sleep Disturbance _____ Cachexia/Weight Loss _____ Nausea _____ Seizures _____ Muscle Spasms _____	

References

1. Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., ... Petersen, K. L. (2007). Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology*, 68(7), 515–521. doi: 10.1212/01.wnl.0000253187.66183.9c
2. Andrae, M. H., Carter, G. M., Shaparin, N., Suslov, K., Ellis, R. J., Ware, M. A., ... Sacks, H. S. (2015). Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. *The Journal of Pain*, 16(12), 1221–1232. doi: 10.1016/j.jpain.2015.07.009
3. Grant, I. (2013). Medicinal Cannabis and Painful Sensory Neuropathy. *AMA Journal of Ethics*, 15(5), 466–469. doi: 10.1001/virtualmentor.2013.15.5.oped1-1305
4. Health Canada. (2018). Information for Health Care Professionals - Cannabis (marihuana, marijuana) and the cannabinoids. Retrieved from <https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids-eng.pdf>
5. Maccallum, C. A., & Russo, E. B. (2018). Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine*, 49, 12–19. doi: 10.1016/j.ejim.2018.01.004
6. Portenoy, R. K., Ganae-Motan, E. D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., ... Fallon, M. T. (2012). Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial. *The Journal of Pain*, 13(5), 438–449. doi: 10.1016/j.jpain.2012.01.003
7. Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 163(7), 1344–1364. doi: 10.1111/j.1476-5381.2011.01238.x
8. The National Academies of Sciences, Engineering, and Medicine. (2017a). The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. (Ch. 4-1). doi: <https://doi.org/10.17226/24625>
9. The National Academies of Sciences, Engineering, and Medicine. (2017b). The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. doi: <https://doi.org/10.17226/24625>
10. Whiting, P. F., Wolff, R. F., Deshpande, S., Nisio, M. D., Duffy, S., Hernandez, A. V., ... Kleijnen, J. (2015). Cannabinoids for Medical Use. *Jama*, 313(24), 2456. doi: 10.1001/jama.2015.6358
11. Zajicek, J. P., Hobart, J. C., Slade, A., Barnes, D., & Mattison, P. G. (2012). Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. *Journal of Neurology, Neurosurgery & Psychiatry*, 83(11), 1125–1132. doi: 10.1136/jnnp-2012-302468